Fri, Mar. 11, 9:17 AM
Jun. 23, 2015, 10:44 AM
- Investors react to the implied dilution of MELA Sciences' (MELA -24.7%) acquisition of PhotoMedex's XTRAC and VTRAC dermatology businesses for $42.5M in cash and the assumption of certain liabilities. MELA funded the deal by issuing senior secured notes and convertible debt to certain institutional investors in a private placement. The transaction includes warrants to purchase 3M shares of common stock at $0.75 per share and $32.5M principal amount of senior secured convertible debentures that are convertible into ~43.3M shares of common stock at $0.75 per share.
- XTRAC is an ultraviolet light excimer laser system. VTRAC is an ultraviolet excimer lamp system. Both businesses generated $30.6M in revenues in 2014, an increase of 41% from the prior year. Gross margin was 60.1%. As of March 2015, there were 640 XTRAC systems installed in the U.S. Over 300K XTRAC procedures were performed on ~19K patients in the U.S. last year.
Jun. 23, 2015, 9:16 AM
Mar. 11, 2015, 12:47 PM
Mar. 11, 2015, 9:11 AM
Mar. 11, 2015, 8:11 AM
- Thinly-traded nano cap Mela Sciences (NASDAQ:MELA) is up 76% premarket on robust volume in response to its disclosure in a regulatory filing that the CPT Editorial Panel accepted the addition of two Category III reimbursement codes, 039XX1T and 039XX2T, to report multi-spectral digital skin lesion analysis of atypical cutaneous lesions, which applies to its MelaFind system.
- The establishment of the codes is the first step in securing Medicare reimbursement. Once the codes are identified, the Department of Health and Human Services sets the specific dollar amount for each one. All third party payments for medical procedures, public or private, key off this amount. Category III codes allow for data collection which is used to evaluate the procedure.
- MelaFind is a hand-held optical device that a dermatologist uses to scan a patient's skin in order to obtain additional information for a decision to biopsy in cases of suspected melanoma.
Mar. 9, 2015, 12:45 PM
Feb. 23, 2015, 12:44 PM
Feb. 19, 2015, 12:46 PM
Feb. 19, 2015, 10:44 AM
- "Small is better" appears to be the recent investment theme in healthcare stocks. Thinly-traded nano cap MELA Sciences (MELA +42.4%) jumps on a 12x surge in volume on no particular news. Shares are up 63% since Tuesday.
- Other recent nano/micro cap bullish moves: (CLRX +102.6%)(TTPH +8.2%)(AKAO +3.7%)(ROSG +1.8%)(HTBX -3.7%)(EGRX +3.7%)(ONCY -12%)(GENE -5%)(WGBS -5.6%)(SGNL -4.2%)
Jan. 2, 2015, 12:50 PM
Jan. 2, 2015, 11:45 AM
Oct. 21, 2014, 1:32 PM
- Thinly-traded nano cap Mela Sciences (MELA +19.5%) rises on a 4x surge in volume albeit on turnover of only 135K shares.
- Yesterday, the SEC declared its S-3 effective. It issued its prospectus today for the sale of up to 21,637,429 shares of common stock by selling stockholders. The July 21, 2014 securities purchase agreement included warrants to purchase up to 10,643,276 shares of common stock at $2.45. This is the only potential source of new capital available to the company. MELA currently exchanges hands for ~$2.21.
- The company's cash balance as of June 30, 2014 was $4.2M. Its cash burn rate is ~$5M per quarter.
Oct. 21, 2014, 12:46 PM
Jul. 22, 2014, 12:47 PM
Aug. 7, 2013, 6:15 PM
- MELA Sciences (MELA): Q2 EPS of -$0.17 in-line.
- Revenue of $144.4K misses by $105.6K. (PR)
MELA Sciences, Inc. is a medical device company, which has focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations. Its flagship product MelaFind, which is a non-invasive, point-of-care... More
Industry: Medical Instruments & Supplies
Country: United States
Other News & PR